Drug Interactions between Baraclude and tepotinib
This report displays the potential drug interactions for the following 2 drugs:
- Baraclude (entecavir)
- tepotinib
Interactions between your drugs
No interactions were found between Baraclude and tepotinib. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Baraclude
A total of 158 drugs are known to interact with Baraclude.
- Baraclude is in the drug class nucleoside reverse transcriptase inhibitors (NRTIs).
- Baraclude is used to treat Hepatitis B.
tepotinib
A total of 288 drugs are known to interact with tepotinib.
- Tepotinib is in the drug class multikinase inhibitors.
- Tepotinib is used to treat Non Small Cell Lung Cancer.
Drug and food interactions
entecavir food
Applies to: Baraclude (entecavir)
ADJUST DOSING INTERVAL: Food delays the oral absorption and reduces the oral bioavailability of entecavir. According to the product labeling, administration of entecavir 0.5 mg with a standard high-fat meal or a light meal resulted in a delay in absorption by 0.25 to 0.75 hours, a decrease in the peak plasma concentration (Cmax) by 44% to 46%, and a decrease in the area under the plasma concentration-time curve (AUC) by 18% to 20% compared to administration in the fasting state.
MANAGEMENT: To ensure maximal oral absorption, entecavir should be administered on an empty stomach at least 2 hours after a meal and 2 hours before the next meal.
References (1)
- (2005) "Product Information. Baraclude (entecavir)." Bristol-Myers Squibb
tepotinib food
Applies to: tepotinib
ADJUST DOSING INTERVAL: Food enhances the oral bioavailability of tepotinib. When tepotinib was administered after a high-fat, high-calorie meal (approximately 800 to 1000 calories; 150 calories from protein, 250 calories from carbohydrate, 500 to 600 calories from fat), tepotinib peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 2-fold and 1.6-fold, respectively, compared to administration under fasted conditions.
MANAGEMENT: Tepotinib should be administered with food at approximately the same time each day.
References (1)
- (2021) "Product Information. Tepmetko (tepotinib)." EMD Serono Inc
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.